Entopsis pursues 'strategic alternatives' for OpsisDx platform

2020 02 06 00 21 0816 Lab Urine Test Strip 400

Entopsis has announced that it will pursue strategic alternatives for its OpsisDx urine-based technology platform that offers a diagnostic test for detecting early-stage cancers.

The company said it has engaged with Berkery Noyes as its financial advisor to assist in the endeavor. OpsisDx detects urine chemical signatures through a proprietary array and delivers results via the company's machine-learning algorithms.

Entopsis said validation studies on OpsisDx initially focused on detecting early-stage cancers, and the platform has now expanded to detect multiple other diseases.

Page 1 of 94
Next Page